New drug hope for rare sarcomas after chemo fails

NCT ID NCT05106777

Ongoing Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a daily oral drug called surufatinib in 47 people with advanced osteosarcoma or soft tissue sarcoma that has not responded to standard chemotherapy. The goal is to see if the drug can slow tumor growth and improve survival. Participants take the drug in 21-day cycles, and researchers track how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Surufatinib (a drug taken by mouth once daily in 21-day cycles)
What this could lead to: If successful, surufatinib could offer a new treatment option for people with advanced sarcoma who have run out of standard chemotherapy options.
What could go wrong: This is a small, early-phase (Phase 2) trial with only 47 participants, so results may not apply to everyone. The drug may not work better than existing treatments and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteosarcoma sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA

Contacts and locations

Locations

Sun Yat-Sen Univerisity

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.